Genocea Biosciences, Inc. (GNCAQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jan 21, 2025, 9:30 AM EST
Genocea Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2016 - 2012 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | 2016 - 2012 |
| Revenue | 1.91 | 1.64 | 1.36 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 40.62% | 20.75% | - | - | - | - | Upgrade
|
| Gross Profit | 1.91 | 1.64 | 1.36 | - | - | - | Upgrade
|
| Selling, General & Admin | 14.64 | 14.71 | 14.39 | 12.04 | 14.31 | 13.43 | Upgrade
|
| Research & Development | 43.81 | 40.12 | 33.96 | 26.95 | 25.21 | 39.2 | Upgrade
|
| Operating Expenses | 58.46 | 54.83 | 48.35 | 38.99 | 39.52 | 52.64 | Upgrade
|
| Operating Income | -56.54 | -53.19 | -46.99 | -38.99 | -39.52 | -52.64 | Upgrade
|
| Interest Expense | -1.07 | -1.12 | -1.5 | -1.6 | -1.7 | -1.7 | Upgrade
|
| Interest & Investment Income | - | - | 0.12 | 0.65 | 0.68 | 0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 19.33 | 20.02 | 4.66 | 0.99 | 12.73 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -38.29 | -34.3 | -43.71 | -38.95 | -27.81 | -54.09 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -2.62 | Upgrade
|
| Other Unusual Items | 1.1 | 1.1 | - | - | - | - | Upgrade
|
| Pretax Income | -37.19 | -33.2 | -43.71 | -38.95 | -27.81 | -56.71 | Upgrade
|
| Net Income | -37.19 | -33.2 | -43.71 | -38.95 | -27.81 | -56.71 | Upgrade
|
| Net Income to Common | -37.19 | -33.2 | -43.71 | -38.95 | -27.81 | -56.71 | Upgrade
|
| Shares Outstanding (Basic) | 70 | 69 | 44 | 21 | 10 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 69 | 47 | 21 | 10 | 4 | Upgrade
|
| Shares Change (YoY) | 29.43% | 47.31% | 125.50% | 100.02% | 188.67% | 1.07% | Upgrade
|
| EPS (Basic) | -0.53 | -0.48 | -0.98 | -1.89 | -2.69 | -15.86 | Upgrade
|
| EPS (Diluted) | -0.53 | -0.48 | -1.11 | -1.89 | -2.69 | -15.86 | Upgrade
|
| Free Cash Flow | -51.33 | -48.66 | -44.24 | -38.87 | -41.48 | -48.78 | Upgrade
|
| Free Cash Flow Per Share | -0.74 | -0.71 | -0.95 | -1.88 | -4.02 | -13.64 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | - | - | - | Upgrade
|
| Operating Margin | -2958.87% | -3241.50% | -3457.62% | - | - | - | Upgrade
|
| Profit Margin | -1946.15% | -2022.91% | -3216.63% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -2685.82% | -2965.14% | -3255.04% | - | - | - | Upgrade
|
| EBITDA | -55.67 | -52.34 | -46.45 | -38.29 | -38.83 | -51.41 | Upgrade
|
| D&A For EBITDA | 0.88 | 0.86 | 0.54 | 0.7 | 0.69 | 1.23 | Upgrade
|
| EBIT | -56.54 | -53.19 | -46.99 | -38.99 | -39.52 | -52.64 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.